Showing 4,061 - 4,080 results of 32,204 for search '(( 50 ((nn decrease) OR (((mean decrease) OR (a decrease)))) ) OR ( a step decrease ))', query time: 1.02s Refine Results
  1. 4061
  2. 4062
  3. 4063
  4. 4064
  5. 4065
  6. 4066
  7. 4067
  8. 4068
  9. 4069
  10. 4070
  11. 4071
  12. 4072
  13. 4073
  14. 4074
  15. 4075

    Image2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  16. 4076

    Image1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIFF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  17. 4077

    Image3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.TIF by Qiao Liu (346535)

    Published 2021
    “…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”
  18. 4078

    Fusion of a granzyme B-mCherry containing lytic granule with the plasma membrane. by Min Ming (785996)

    Published 2015
    “…The arrowhead indicates a lytic granule which decreased in fluorescence and generated a cloud of fluorescence while fusing. …”
  19. 4079
  20. 4080